Gut microbiota-associated predictors as biomarkers of neoadjuvant treatment response in rectal cancer-a systematic review
Astghik Stepanyan(University of Padua), Licia Laurino(University of Padua), Giulia Capelli(University of Padua), Giulia Becherucci(University of Padua), Quoc Riccardo Bao(University of Padua), Chiara Cipollari(La Salle University), Ivana Cataldo(Ospedale SS. Annunziata), Giovanni Bertalot(University of Trento), Francesca Bergamo(Istituto Oncologico Veneto), Salvatore Candioli(AULSS 2 Marca Trevigiana), Mario Godina(ASL Roma), Alberto Brolese, Loretta Di Cristofaro, Stefano Brignola(University of Padua), Valentina Chiminazzo(University of Padua), Matteo Fassan(University of Padua), Luca Dal Santo(University of Padua), Romeo Bardini(University of Padua), Michela Campi(Ca' Foncello Hospital), Francesco Cavallin, Gianluca Businello(University of Padua), Antonella D’Angelo(University of Padua), Marco Agostini(University of Padua), Marco Brolese(Azienda Ospedale - Università Padova), Gianluca Buzzi(ASL Roma), Andromachi Kotsafti(Istituto Oncologico Veneto), Lavinia Ceccarini(Ospedale San Bassiano), Mario Guerrieri(Marche Polytechnic University), Carlotta Ceccon(University of Padua), Luca Facci(University of Padua), Ottavia De Simoni(Istituto Oncologico Veneto), Mattia Barbareschi(University of Trento), Imerio Angriman, Boris Franzato(Istituto Oncologico Veneto), Giovanni Bordignon(AULSS 2 Marca Trevigiana), Roberto Cola(ASL Roma), Vincenza Guzzardo(University of Padua), Corrado Da Lio(Ospedale di Mirano), Michele Antoniutti(Ca' Foncello Hospital), A P Dei Tos(University of Padua), Ignazio Castagliuolo(University of Padua), Antonio Rosato(Istituto Oncologico Veneto), Dario Gregori(University of Padua), Laura Gavagna(ASL Roma), Barbara Di Camillo(University of Padua), Andrea Baldo(University of Bern), on behalf of the IMMUNOREACT Study Group, Silvio Guerriero
Cited by 0
Related Papers
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
|Nature Genetics|2013|709
A MicroRNA Targeting Dicer for Metastasis Control
|Cell|2010|665